Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- Community Is Mourning the Loss of a Keene Baby to Rare Cancer on September 18, 2018 at 12:48 pm
Eliana Rouleau, daughter of Adrian and Meghan Rouleau, was diagnosed with acute myeloid leukemia Dec. 24, 2017. The family chronicled little Eliana's last year of life on a Facebook page dedicated to ... […]
- Software could lead to personalized leukemia treatments on September 18, 2018 at 11:06 am
Early findings from a new study could help in the development of immune-based treatments personalized to people with acute myeloid leukemia who are undergoing stem cell transplantation, researchers re... […]
- Chemotherapy combination appears safe for elderly patients with acute myeloid leukemia on September 17, 2018 at 5:09 am
Treatment with the combination of cladribine and low-dose cytarabine alternating with decitabine appeared safe and effective among older patients with newly diagnosed acute myeloid leukemia, according ... […]
- Acute Myeloid Leukemia Treatment Market 2018 Global Expected to Grow at CAGR of 5.3% and Reach to USD 1.2 Billion Forecast to 2023 on September 14, 2018 at 9:09 pm
Acute myeloid leukemia (AML) is a cancer of the myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid buildup of abnormal white blood cells ... […]
- Recognizing Predisposition Syndromes Can Impact Pediatric MDS and AML Treatment on September 13, 2018 at 7:25 pm
Early identification of inherited predisposition to forms of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in pediatric patients can assist in treatment decisions and selection for f... […]
- Chromosomal Abnormality May Hold Promise in Treating AML on September 13, 2018 at 8:25 am
The novel agent lurbinectedin (PM01183) does not appear to demonstrate promise in treating acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)—but the presence of a certain chromosomal abno... […]
- Drug combination targets pre-leukemia stem cells on September 12, 2018 at 7:13 pm
In early stages, MDS can usually be managed with supportive care. However, as the disease progresses, about one in three cases of high-risk MDS will evolve into acute myeloid leukemia (AML), an extrem... […]
- How Acute Myeloid Leukemia Is Treated at MSK: An Interview with Martin Tallman on September 11, 2018 at 10:11 am
An icon showing an arrow pointing to the right. An icon showing an arrow pointing to the right. Back An icon showing an arrow pointing to the right. Portrays time in the form of months and days. Make ... […]
- The Soil for the Seeds: Investigating the Microenvironment of Acute Myeloid Leukemia on September 11, 2018 at 9:17 am
As a predoctoral student in the Integrated Biomedical Sciences Graduate Program at The Ohio State University in 2005, Bethany Mundy-Bosse, PhD, had plans to focus her graduate work on basic stem cell ... […]
via Bing News